WebSep 18, 2024 · Cisplatin is a medication used to manage and treat solid tumors and hematologic malignancies. It is in the alkylating agent class of cytotoxic medications. … WebA quick look at the research seems to show cisplatin is less risky than carboplatin in terms of secondary cancer (like leukemia). A study on women who were treated with platinum …
Cisplatin Article - StatPearls
WebFeb 16, 2024 · Common side effects of cisplatin may include: hearing problems; kidney problems; numbness or tingling; nausea, vomiting; or. bone marrow suppression. This is … WebJan 24, 2024 · Secondary Cancers in Hodgkin Disease Solid Tumors Radiation therapy may also increase later risk of solid tumors, especially thyroid cancer and breast cancer. Unlike blood-related cancers, the risk is highest 10 to 15 years or more after treatment is finished. 13 Cognitive Concerns so wingo
Predicted Secondary Malignancies following Proton versus …
WebPlatinum chemotherapy, particularly cisplatin, is commonly associated with electrolyte imbalances, including hypomagnesemia, hypokalemia, hypophosphatemia, hypocalcemia and hyponatremia. The corpus of literature on these dyselectrolytemias is large; the objective of this review is to synthesize the … WebSecondary actions. Search Journals Articles Documentation API OAI-PMH Widgets ... Integrin α6β4 signals through DNA damage response pathway to sensitize breast cancer cells to cisplatin Min Chen, Min Chen, Brock Marrs, Lei Qi, Teresa Knifley, Heidi L. Weiss, Heidi L. Weiss, John A. D’Orazio, John A. D’Orazio, ... WebFeb 27, 2024 · The prognosis of patients with recurrent or metastatic head and neck squamous cell cancer is generally poor. The median survival in most series is 6 to 15 months depending on patient- and disease-related factors. Symptom-directed care plays an important role in the management of these patients. team meeting invitation template